Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
作者信息
Savioli Felicio, Claro Maurício, da Silva Ramos Fernando Jose, Pastore Laerte
机构信息
Critical Care Medicine Department, Hospital Sírio Libanês, Sao Paulo, Brazil.
出版信息
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221087692. doi: 10.1177/10760296221087692.
Abstract
摘要
相似文献
1
Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?新冠病毒肺炎血栓栓塞患者的凝血因子 VIII、纤维蛋白原与肝素抵抗：我们应如何管理抗凝治疗？
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221087692. doi: 10.1177/10760296221087692.
2
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.住院 COVID-19 患者的凝血病：治疗性抗凝与标准治疗作为对 COVID-19 大流行的快速反应的实用随机对照试验 (RAPID COVID COAG - RAPID 试验)：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
3
Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis.我们是否应该考虑对新冠肺炎患者进行肝素预防？一项系统评价和荟萃分析。
J Thromb Thrombolysis. 2021 Apr;51(3):830-832. doi: 10.1007/s11239-020-02253-x. Epub 2020 Aug 20.
4
Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism.COVID-19 患者在接受抗凝治疗静脉血栓栓塞症时出现大出血和死亡。
J Thromb Thrombolysis. 2022 Oct;54(3):431-437. doi: 10.1007/s11239-022-02666-w. Epub 2022 Jun 10.
5
Coagulation, anticoagulation and pancreatic carcinoma.凝血、抗凝与胰腺癌
Nat Clin Pract Gastroenterol Hepatol. 2008 Aug;5(8):445-55. doi: 10.1038/ncpgasthep1184. Epub 2008 Jul 1.
6
How do palliative physicians manage venous thromboembolism?
Palliat Med. 1997 Nov;11(6):462-8. doi: 10.1177/026921639701100606.
7
Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status.1125 例 COVID-19 患者的全身性和静脉血栓栓塞、死亡率和出血风险的危险因素：与抗凝状态的关系。
Aging (Albany NY). 2021 Mar 26;13(7):9225-9242. doi: 10.18632/aging.202769.
8
Effect of anticoagulation on the lysis of filter entrapped thromboembolism in dogs.
J Surg Res. 1985 Apr;38(4):391-9. doi: 10.1016/0022-4804(85)90053-8.
9
Heparin use during pregnancy.孕期使用肝素。
Tunis Med. 2002 Jun;80(6):297-305.
10
[Low-molecular-weight heparins].
Internist (Berl). 1998 Apr;39(4):414-5.
引用本文的文献
1
Heparin resistance management during cardiac surgery: a literature review and future directions.心脏手术期间肝素抵抗的管理：文献综述及未来方向。
J Extra Corpor Technol. 2024 Sep;56(3):136-144. doi: 10.1051/ject/2024015. Epub 2024 Sep 20.
本文引用的文献
1
Heparin Resistance - Clinical Perspectives and Management Strategies.肝素抵抗——临床观点与管理策略
N Engl J Med. 2021 Aug 26;385(9):826-832. doi: 10.1056/NEJMra2104091.
2
Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.重症监护病房中感染 SARS-CoV2 的患者的肝素剂量、水平和耐药性。
Int J Lab Hematol. 2021 Dec;43(6):1284-1290. doi: 10.1111/ijlh.13543. Epub 2021 Apr 14.
3
The coagulopathy, endotheliopathy, and vasculitis of COVID-19.COVID-19 的凝血功能障碍、血管内皮功能障碍和血管炎。
Inflamm Res. 2020 Dec;69(12):1181-1189. doi: 10.1007/s00011-020-01401-6. Epub 2020 Sep 12.
4
Differentiating biochemical from clinical heparin resistance in COVID-19.区分COVID-19中生化性与临床性肝素抵抗
J Thromb Thrombolysis. 2020 Nov;50(4):1015-1016. doi: 10.1007/s11239-020-02259-5.
5
Heparin resistance in COVID-19 patients in the intensive care unit.COVID-19 患者在重症监护病房中肝素耐药。
J Thromb Thrombolysis. 2020 Aug;50(2):287-291. doi: 10.1007/s11239-020-02145-0.
6
Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan.武汉48例重症新型冠状病毒肺炎患者下肢深静脉血栓形成的极高发生率
Circulation. 2020 Jul 14;142(2):181-183. doi: 10.1161/CIRCULATIONAHA.120.047407. Epub 2020 May 15.
7
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.抗凝治疗的重症 COVID-19 患者中静脉血栓栓塞事件发生率高。
J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27.
8
Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.感染新型冠状病毒（SARS-CoV-2）患者的血栓栓塞事件及明显的肝素抵抗
Int J Lab Hematol. 2020 Jun;42 Suppl 1(Suppl 1):19-20. doi: 10.1111/ijlh.13230.
9
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
10
To be or not to be a case of heparin resistance.是否为肝素抵抗病例。
J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):145-148. doi: 10.1080/20009666.2018.1466599. eCollection 2018.
Zotero 插件